Are Patients With High-Risk Polycythemia Vera Receiving Cytoreductive Medications? A Retrospective Analysis of Real-World Data

A retrospective analysis found that only 42.0% and 18.9% of patients with high-risk and low-risk polycythemia vera, respectively, received cytoreductive therapy overall, despite guidelines recommending the treatment as part of risk-adapted therapy.

Experimental Hematology & Oncology